We collect data from the public registry at ClinicalTrials.gov, which is managed by the US National Library of Medicine. We plan on adding more sources in the future, e.g. the UK Clinical Trials Gateway (UKCTG). We use AI algorithms to transform free-text data into a computer-friendly representation that can be used for matching patients and trials.

TrialJectory’s compares your medical information to each trial’s enrolment criteria; We recommend the trials that match the profile you’ve provided. Trials are ranked (in the following order) by:
The amount of information you provided that this trial requires. You can choose to skip any question we ask, but the more information you provide the better our match can be. We rank trials for which you have provided all relevant information first.
Interventional trials are ranked above observational trials, and trials without placebos above trials that may administer placebos.
Closer trials are ranked above farther trials.

Once you click the “Apply” button, the TrialJectory medical team will view your profile and make sure we have all the required information. We will then approach the trial coordinator or primary investigator on your behalf. You, and your oncologist, will also be able to contact the investigator directly to learn more about the purpose of the trial, its benefits, the drugs and/or procedures that are part of the trial, side effects, etc. Once you decide to apply to a trial, you will have to sign a consent form. Additional tests (such as blood test, CT/MRI etc.) may be required by the trial recruiting team. Only after the clinical trial team has gathered all the information, will you need to make a final decision whether to enroll. Note that you can withdraw from a trial at any point for whatever reasons, even after the trial has started.

A placebo (often called a sugar pill) is an agent that has no effect on the disease or patient, and is used in some clinical trials as a control/ comparator arm. These days many studies do not have a “placebo” arm, but rather a “standard of care” arm, meaning that patients that are assigned to the “standard of care” arm receive the available/approved treatment that is the standard care for their condition.
In an “open label” clinical trial both clinicians and patients know which treatment is being administered. In a “blind” or a “double blind” trial neither clinicians nor patients know which treatment is being administered. However, it’s important to note that even in blind trials patients are almost always offered, at the minimum, the current standard of care, meaning you will receive treatment while in trials. In trials where this is not the case (i.e., patients are not getting the standard treatment), the issue will be communicated to you by the trial coordinator/investigator.

We are a team of researchers, data scientists, oncologists and patients like you, with accumulated experience of over 100 years. We decided to use our expertise to help cancer patients get better visibility to treatment options and help them get better. We realized that by building a smart machine that introduces patients and their doctors to the right clinical trials we can empower them to make better and well-informed decisions about treatment.
While matching patients with trials, we also help the pharmaceutical industry expedites drugs approval and support the entire fight against cancer.

We use clincaltrials.gov. to constantly update our database with new trials and trials that have started recruiting patients.